Slideshow

7 New Drugs for Neurologists

Author(s):

Julie Bowen

Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.

Related Videos
Anne Marie Morse, DO, FAASM
1 KOL is featured in this series.
John Winkelman, MD, PhD
1 KOL is featured in this series.
1 KOL is featured in this series.
Sarah Anderson, PharmD, NBC-HWC
1 KOL is featured in this series.
Related Content
This Week on NeurologyLive® — October 21, 2024
October 21st 2024

This Week on NeurologyLive® — October 21, 2024

NeurologyLive® Staff
Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy
October 18th 2024

Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy

Marco Meglio
NeurologyLive® Friday 5 — October 18, 2024
October 18th 2024

NeurologyLive® Friday 5 — October 18, 2024

NeurologyLive® Staff
Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis
October 4th 2024

Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

Marco Meglio
Robert A. Hauser, MD, MBA (Credit: USF Health)
Published: October 17th 2024 | Updated: October 21st 2024

FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment

Isabella Ciccone, MPH
NeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Legs Syndrome Treatment
October 16th 2024

NeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Legs Syndrome Treatment

John Winkelman, MD, PhD Isabella Ciccone, MPH
© 2024 MJH Life Sciences

All rights reserved.